Atlas Trials

Acute Myeloid Leukemia Post Cytotoxic Therapy

14 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Acute Myeloid Leukemia Post Cytotoxic Therapy

RecordFirmDate
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study (NCT04726241)PedAL BCU, LLC2022-04-18
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia (NCT04214249)National Cancer Institute (NCI)2021-02-17
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (NCT04284787)National Cancer Institute (NCI)2021-02-16
Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation (NCT03953898)National Cancer Institute (NCI)2020-08-04
Liposome-encapsulated Daunorubicin-Cytarabine, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia (NCT02642965)Children's Oncology Group2016-05-02
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia (NCT02381548)National Cancer Institute (NCI)2015-08-18

Track Acute Myeloid Leukemia Post Cytotoxic Therapy automatically

Every clearance here is in the API, with alerts when new ones post.